| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Models |
§
From the Institute of Pathology,*
I. Department of
Medicine, Division of Pathophysiology,
and
Institute of Clinical Chemistry,¶
University of
Mainz, Germany; IRBM P. Angletti,
Pomezia,
Rome, Italy; and Boehringer Ingelheim Research
Group,§
Mainz, Germany
Cytokines interact not only with membrane anchored receptors, but also with specific soluble receptors which circulate in the bloodstream. In general, soluble cytokine receptors such as soluble tumor necrosis factor receptor, soluble interleukin 1 receptor, and soluble interleukin 4 receptor compete with their membrane-bound counterparts for the ligands and therefore act as antagonists. In contrast, soluble receptors for cytokines of the interleukin-6 (IL-6) family complex with their ligands act agonistically. Interestingly, the complex of IL-6 and the soluble interleukin 6 receptor (sIL-6R) activates target cells that do not express the membrane-bound IL-6R and therefore cannot respond to IL-6. To identify cellular responses that are due to IL-6/sIL-6R but not to IL-6 alone, IL-6/sIL-6R double-transgenic mice were generated and compared with IL-6 single-transgenic mice. IL-6/sIL-6R transgenic mice develop a severe phenotype showing 1) marked hepatocellular hyperplasia frequently surrounded by peliosis and necrosis, 2) significant acceleration and aggravation of plasmacytoma formation, and 3) excessive activation of extramedullary hematopoiesis in spleen and liver followed by a subsequent increase of all cellular components in the peripheral blood. These in vivo data suggest that the sIL-6R recruits primarily unresponsive cell populations such as hematopoietic progenitor cells and hepatocytes to IL-6-induced proliferation, but also enhances the known mitogenic effect of IL-6 on plasma cells and thereby contributes to plasmacytoma formation.
This article has been cited by other articles:
 |
|
 |
|
  Y. Tang, K. Kitisin, W. Jogunoori, C. Li, C.-X. Deng, S. C. Mueller, H. W. Ressom, A. Rashid, A. R. He, J. S. Mendelson, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-{beta} and IL-6 signaling PNAS, February 19, 2008; 105(7): 2445 - 2450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Jenkins, A. W. Roberts, C. J. Greenhill, M. Najdovska, T. Lundgren-May, L. Robb, D. Grail, and M. Ernst Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis Blood, March 15, 2007; 109(6): 2380 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, K. P. Mann, and J. T. Holden T-Cell-Rich B-Cell Lymphoma Presenting in the Spleen: A Clinicopathologic Analysis of 3 Cases International Journal of Surgical Pathology, January 1, 2004; 12(1): 31 - 37. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Wallenius, K. Wallenius, M. Hisaoka, J. Sandstedt, C. Ohlsson, M. Kopf, and J.-O. Jansson Retarded Liver Growth in Interleukin-6-Deficient and Tumor Necrosis Factor Receptor-1-Deficient Mice Endocrinology, July 1, 2001; 142(7): 2953 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. JONES, S. HORIUCHI, N. TOPLEY, N. YAMAMOTO, and G. M. FULLER The soluble interleukin 6 receptor: mechanisms of production and implications in disease FASEB J, January 1, 2001; 15(1): 43 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Brunello, J. Weissenberger, A. Kappeler, C. Vallan, M. Peters, S. Rose-John, and J. Weis Astrocytic Alterations in Interleukin-6/Soluble Interleukin-6 Receptor {alpha} Double-Transgenic Mice Am. J. Pathol., November 1, 2000; 157(5): 1485 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. GALUN, E. ZEIRA, O. PAPPO, M. PETERS, and S. ROSE-JOHN Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury FASEB J, October 1, 2000; 14(13): 1979 - 1987. [Abstract] [Full Text]
|
|
|
|
 |
|
 K L STREETZ, T LUEDDE, M P MANNS, and C TRAUTWEIN Interleukin 6 and liver regeneration Gut, August 1, 2000; 47(2): 309 - 312. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mullberg, T. Geib, T. Jostock, S. H. Hoischen, P. Vollmer, N. Voltz, D. Heinz, P. R. Galle, M. Klouche, and S. Rose-John IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-6 J. Immunol., May 1, 2000; 164(9): 4672 - 4677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ezure, T. Sakamoto, H. Tsuji, J. G. Lunz III, N. Murase, J. J. Fung, and A. J. Demetris The Development and Compensation of Biliary Cirrhosis in Interleukin-6-Deficient Mice Am. J. Pathol., May 1, 2000; 156(5): 1627 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Funamoto, Y. Fujio, K. Kunisada, S. Negoro, E. Tone, T. Osugi, H. Hirota, M. Izumi, K. Yoshizaki, K. Walsh, et al. Signal Transducer and Activator of Transcription 3 Is Required for Glycoprotein 130-mediated Induction of Vascular Endothelial Growth Factor in Cardiac Myocytes J. Biol. Chem., March 31, 2000; 275(14): 10561 - 10566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Thabard, S. Barille, M. Collette, J.-L. Harousseau, M.-J. Rapp, R. Bataille, and M. Amiot Myeloma Cells Release Soluble Interleukin-6R{{alpha}} in Relation to Disease Progression by Two Distinct Mechanisms: Alternative Splicing and Proteolytic Cleavage Clin. Cancer Res., October 1, 1999; 5(10): 2693 - 2697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peters, A. M. Muller, and S. Rose-John Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis Blood, November 15, 1998; 92(10): 3495 - 3504. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
